End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber’s $500M experiment; Vertex’s pain breakthrough; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid a week packed with earn­ings and big news, the End­points team al­so brought a sol­id line­up of orig­i­nal re­port­ing. See if you missed any­thing!

End of Aduhelm’s road

Bio­gen will stop sales and de­vel­op­ment of its con­tro­ver­sial Alzheimer’s drug Aduhelm, walk­ing away from a drug that was ap­proved against out­side ex­perts’ ad­vice, led to con­gres­sion­al in­quiries and faced push­back over its cost and ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.